Myth: You Have to Be 'Obese Enough' for Mounjaro or Ozempic to Make Sense

A YouGov poll recently asked people a simple question: should the NHS give Mounjaro and Ozempic to people who are overweight but not technically obese? Most people's gut reaction is no, because the assumption baked into that question is that these drugs are only "worth it" once someone crosses the obesity line on a BMI chart.

That assumption is wrong, or at least a lot shakier than it sounds.

Not medical advice: This article explains what the research shows about weight-loss drugs and BMI thresholds. It is not a recommendation for you personally. Talk to a doctor about your own health before starting or stopping any medication.

The Myth, In Plain English

Here's the belief driving most of the "no" votes in that poll: weight-loss drugs are a last resort for people with serious obesity, and giving them to someone who's "just a bit overweight" is a waste of a limited resource, or worse, enabling vanity.

It's an understandable position. BMI of 30+ (obese) sounds like a medical problem. BMI of 25-29.9 (overweight) sounds like something a person should just fix with a gym membership.

But BMI was never designed to be a light switch that flips from "fine" to "at risk" at one exact number. It's a rough screening tool, not a diagnosis. And the research on who actually benefits from GLP-1 drugs like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) doesn't line up neatly with that BMI cutoff either.

Why This Myth Sticks Around

Part of it is simple math. Healthcare systems like the NHS have limited budgets, and BMI 30 is an easy, measurable line to draw when rationing an expensive drug. It's not malicious, it's a practical shortcut.

Part of it is also cultural. "Overweight" has been treated as a cosmetic category for decades, while "obese" gets treated as medical. That framing shapes how people vote in polls like this one, even when the health data underneath doesn't respect the same line.

And here's who benefits from the myth sticking around: insurers and health systems save money by using a strict BMI cutoff, because it shrinks the pool of people who qualify. That's a legitimate cost-control decision, but it's a budget decision dressed up as a medical one.

What the Research Actually Shows About BMI and Benefit

This is the part that should make people rethink the poll question entirely.

Does BMI Alone Predict Who Benefits from GLP-1 Drugs?

Not really. The metabolic risk that these drugs actually target, high blood pressure, poor blood sugar control, fatty liver, cardiovascular strain, doesn't switch on at BMI 30. It builds gradually, and it can already be present in someone who's "just overweight," especially if that weight is concentrated around the waist.

A large population cohort study published in the BMJ looked at tirzepatide's effect on cardiovascular events and found meaningful reductions in major cardiac events when the drug was added to standard care. Nothing in that risk reduction depended on the patient starting above a specific BMI threshold, it depended on their actual metabolic risk profile.

A companion analysis in the same journal on tirzepatide and cardiovascular outcomes makes a similar point: the drug's cardiovascular benefit tracks with metabolic improvement, not with how "obese" someone was on paper before starting.

Separately, a post-hoc analysis of the SURMOUNT-1 trial tracked long-term changes in cardiovascular risk biomarkers with tirzepatide and found improvements in blood pressure, cholesterol, and inflammation markers that showed up well before patients reached "obese" weight-loss milestones. In other words, the health benefit starts kicking in during the overweight range too, it doesn't wait for a BMI number.

What Does the Global Health Community Actually Recommend?

This is where it gets more honest, and more uncomfortable for a simple "yes or no" poll question. A recent review of WHO's GLP-1 recommendations points out that global guidance on these drugs is still caught between promise, scientific uncertainty, and unequal access. The authors don't pretend there's a clean answer, they flag that guidelines built around strict BMI cutoffs risk leaving out people who have obesity-related health problems (like early type 2 diabetes or fatty liver) but a lower BMI number, particularly across different ethnic groups where metabolic risk shows up at lower BMIs.

That last point matters more than it gets credit for. Research has repeatedff to show that some populations, including South Asian and East Asian groups, develop the same metabolic complications as white European patients, but at meaningfully lower BMI numbers. A blanket "obese only" rule can systematically under-treat exactly the people research says are more vulnerable.

What About the People Just Below the Obesity Line?

The Phase 3 SYNCHRONIZE-JP trial testing survodutide in Japanese participants with obesity was specifically designed with this in mind, East Asian obesity thresholds are lower than Western ones precisely because metabolic risk shows up earlier. That's a tacit admission, built right into trial design, that a single universal BMI cutoff doesn't reflect who actually needs treatment.

What Nobody Can Answer Yet

To be fair to the "no" side of that poll, there are real open questions, and pretending otherwise would be dishonest.

Nobody has run a large, long-term trial specifically comparing outcomes for "overweight but not obese" patients against a placebo group over five or ten years. Most of the headline trials, SURMOUNT, STEP, SURPASS, enrolled people who were already obese or had obesity-related conditions. We don't have the same depth of data for the just-overweight population, which means claims about long-term benefit in that group are reasonable extrapolations, not proven fact.

There's also the resource question, which is genuinely unresolved. Expanding NHS access to a much larger population would cost more money, at least in the short term, even if it prevents expensive complications later. Whether that trade-off pays off system-wide is a health economics question, not a medical one, and it's still being modeled.

And side effects don't disappear just because someone's starting weight is lower. Nausea, GI symptoms, and rarer issues still apply. If you're curious about what those look like in practice, our guide to GLP-1 side effects covers what to expect regardless of your starting BMI.

What This Actually Changes

If you've been telling yourself "I'm not overweight enough for this to be worth discussing with a doctor," the research suggests that's the wrong filter. The better question isn't "what's my BMI number", it's "do I have the metabolic risk factors these drugs are shown to improve," things like blood pressure, blood sugar, or fatty liver markers.

That doesn't mean everyone who's a little overweight should run out and get a prescription. It means the BMI-only gatekeeping that shaped that YouGov poll question is a simplification of something messier and more individual. Results vary a lot person to person even among people who do qualify by BMI, something research on why GLP-1 weight loss results vary so much explains in more depth.

If you're weighing your own options, it's worth understanding the differences between the major drugs before you even get to the eligibility conversation, our breakdown of who tends to get which GLP-1 drug first is a good starting point, and this comparison of the best GLP-1 options for weight loss in 2026 covers how doctors are actually thinking about candidacy today.

The honest takeaway from that YouGov poll isn't "yes, expand it" or "no, keep the line." It's that the line itself deserves more scrutiny than a BMI chart gives it.

---

Medical Disclaimer: The information on this website is for educational and informational purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide protocol, medication, or supplement regimen. Individual results vary. This article shares published research and public reporting, not medical recommendations.

Sources

1. Tirzepatide and the risk of atherosclerotic cardiovascular events: population based cohort study, BMJ, 2026
2. Tirzepatide and cardiovascular outcomes, BMJ, 2026
3. Comprehensive Long-Term Changes in Cardiovascular Risk Biomarkers With Tirzepatide: A SURMOUNT-1 Post Hoc Analysis, Journal of the American College of Cardiology, 2026
4. From obesity guideline to diabetes practice: WHO GLP-1 recommendations between promise, uncertainty and global inequity, 2026
5. Survodutide for the Treatment of Obesity Disease in Japanese Participants: SYNCHRONIZE-JP Trial, Diabetes, Obesity & Metabolism, 2026